TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28246888

Group type: EXPERIMENTAL
Intervention: Simvastatin (S)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pravastatin (P)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 25690998

Group type: EXPERIMENTAL
Intervention: RVPAS group
Number of subjects: 275

Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt group
Number of subjects: 275
Study: 23269773

Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention (scripted CD and guide booklet, supplemented by four scripted, 20-minute weekly training calls)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Attention control condition (four scripted, 20-minute weekly training calls)
Number of subjects: 313
Study: 21501482

Group type: EXPERIMENTAL
Intervention: Ertapenem 3 days
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ampicillin-Sulbactam 3 days
Number of subjects: 142
Study: 17919835

Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy with or without concurrent chemotherapy
Number of subjects: 57
Study: 16615971

Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 mug (CIC40)
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 mug (CIC80)
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 mug (CIC160)
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1031
Study: 12872086

Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Number of subjects: 249

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 249
Study: 16570467

Group type: EXPERIMENTAL
Intervention: Early Intervention (EI) including cognitive behavioral skills training and biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonintervention (NI)
Number of subjects: 0
Study: 10230191

Group type: EXPERIMENTAL
Intervention: Naltrexone, 1.0 mg/kg, administered daily for 2 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo, administered daily for 2 weeks
Number of subjects: 24
Study: 8752609

Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (bilateral tubal ligation)
Number of subjects: 20
Study: 1819154

Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 6411791

Group type: EXPERIMENTAL
Intervention: Intravenous mixture of eight essential l-amino acids, hypertonic dextrose, and vitamins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypertonic dextrose and vitamins alone
Number of subjects: 0
Study: 27908668

Group type: EXPERIMENTAL
Intervention: Exposure near a steel mill
Number of subjects: 61

Group type: COMPARATOR
Intervention: Exposure at a location five kilometres away from the steel mill
Number of subjects: 61
Study: 26563497

Group type: EXPERIMENTAL
Intervention: Salidroside (Sal) 20 mg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Salidroside (Sal) 40 mg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Salidroside (Sal)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: RIP140/NF-κB signaling
Number of subjects: 5

Group type: COMPARATOR
Intervention: Clopidogrel (7.5 mg/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Vehicle group
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 5
Study: 24737301

Group type: EXPERIMENTAL
Intervention: Ajust
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MiniArc
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TVT Secur System
Number of subjects: 120
Study: 23091157

Group type: EXPERIMENTAL
Intervention: T4 with commercially available synbiotic Duolac, containing 500 cfu of both Lactobacillus acidophilus and Streptococcus faecium with the addition of lactose (0.001 mg/embryo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: T3 and T4 groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: T1, T2, T3, T4 (treated groups)
Number of subjects: 60

Group type: COMPARATOR
Intervention: C group (control with physiological saline)
Number of subjects: 60
Study: 19085044

Group type: EXPERIMENTAL
Intervention: Schistosomal infection group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (without schistosomal infection)
Number of subjects: 100
Study: 17894913

Group type: EXPERIMENTAL
Intervention: Epidural diamorphine (5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular diamorphine (5 mg)
Number of subjects: 60
Study: 14685103

Group type: EXPERIMENTAL
Intervention: Filgrastim (recombinant human granulocyte colony-stimulating factor)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12236325

Group type: EXPERIMENTAL
Intervention: High perceived control over aversive noise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low perceived control over aversive noise
Number of subjects: 32
Study: 9684386

Group type: EXPERIMENTAL
Intervention: 8 mg/day buprenorphine
Number of subjects: 736

Group type: COMPARATOR
Intervention: 1 mg/day buprenorphine
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: 4 mg/day buprenorphine
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: 16 mg/day buprenorphine
Number of subjects: 736
Study: 8210019

Group type: EXPERIMENTAL
Intervention: Low-dose epidural anaesthesia using 0.375% bupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 50
Study: 2702250

Group type: EXPERIMENTAL
Intervention: Alipase (P) - 9 capsules/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Eurobiol (E) - 3 vials/day
Number of subjects: 35
Study: 31919090

Group type: EXPERIMENTAL
Intervention: ofatumumab-CHL (O-CHL)
Number of subjects: 383

Group type: COMPARATOR
Intervention: chlorambucil (CHL)
Number of subjects: 383
Study: 31888733

Group type: EXPERIMENTAL
Intervention: 22G Franseen needle
Number of subjects: 520

Group type: COMPARATOR
Intervention: 22G conventional needle
Number of subjects: 520
Study: 28728565

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (patients who did not achieve sDFR)
Number of subjects: 60
Study: 24942481

Group type: EXPERIMENTAL
Intervention: Behavioural therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23773041

Group type: EXPERIMENTAL
Intervention: Distrust (untrustworthy interaction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distrust (priming manipulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distrust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distrust (when dissimilarity-focus was impaired)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trust (trustworthy interaction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trust-unrelated interaction
Number of subjects: 0
Study: 21969870

Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir
Number of subjects: 2413

Group type: COMPARATOR
Intervention: Placebo (Control group from the Vaccine Trial)
Number of subjects: 2413
Study: 20434251

Group type: EXPERIMENTAL
Intervention: Welfare-to-work
Number of subjects: 8393

Group type: COMPARATOR
Intervention: Traditional welfare benefits
Number of subjects: 8393
Study: 18098357

Group type: EXPERIMENTAL
Intervention: Mid-axial injection technique (MAI technique)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional injection technique (CI technique)
Number of subjects: 103
Study: 16270608

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) via propofol and remifentanil infusion
Number of subjects: 56

Group type: COMPARATOR
Intervention: Inhaled sevoflurane with incremental doses of fentanyl
Number of subjects: 56
Study: 12398959

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 9934892

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 18

Group type: COMPARATOR
Intervention: 5% albumin
Number of subjects: 18
Study: 7484777

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2249378

Group type: EXPERIMENTAL
Intervention: labetalol (200 to 1600 mg/day)
Number of subjects: 292

Group type: COMPARATOR
Intervention: atenolol (50 to 100 mg/day)
Number of subjects: 292
Study: 7317247

Group type: EXPERIMENTAL
Intervention: Equipotent doses (UD95) of thiopentone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Equipotent doses (UD95) of Althesin
Number of subjects: 48
Study: 31202641

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 27789807

Group type: EXPERIMENTAL
Intervention: N95 respirators (compliant and non-compliant)
Number of subjects: 1074

Group type: COMPARATOR
Intervention: Non-compliant N95 wearers
Number of subjects: 1074
Study: 25567775

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) for 12 months, 2-3 sessions/week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (inactive)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 42
Study: 23981722

Group type: EXPERIMENTAL
Intervention: Black seed oil (40-80 mg/kg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20227261

Group type: COMPARATOR
Intervention: Control diet providing a 500kcal/day deficit, with 500‐600mg/day dietary calcium
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Calcium-supplemented diet with 800mg/day of calcium as calcium carbonate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Milk diet providing a 500kcal/day deficit and containing three servings of low‐fat milk
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Soy milk diet providing a 500kcal/day deficit and containing three servings of calcium fortified soy milk
Number of subjects: 100
Study: 19248543

Group type: EXPERIMENTAL
Intervention: Optimized Prolate Ablation (OPA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional Ablation (Control)
Number of subjects: 14
Study: 17224000

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 120

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 120
Study: 14725704

Group type: EXPERIMENTAL
Intervention: Cystotomy with capitonnage (Group A, n = 32 patients, n = 38 cysts)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cystotomy without capitonnage (Group B, n = 27 patients, n = 32 cysts)
Number of subjects: 59
Study: 12575606

Group type: EXPERIMENTAL
Intervention: Sini Decoction (SND) treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no SND treatment)
Number of subjects: 22
Study: 9398810

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8201388

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (FAC: fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 2624

Group type: COMPARATOR
Intervention: Observation (surgery alone)
Number of subjects: 2624

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (FAC)
Number of subjects: 2624

Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 2624
Study: 3365530

Group type: EXPERIMENTAL
Intervention: Low-dose indomethacin (50 mg/day) combined with paracetamol (4 g/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: High-dose indomethacin (150 mg/day)
Number of subjects: 17
Study: 30358019

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (PR-T)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Immediate-release tacrolimus (IR-T)
Number of subjects: 33
Study: 27274772

Group type: EXPERIMENTAL
Intervention: US participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with prior CVD
Number of subjects: 0

Group type: COMPARATOR
Intervention: European participants
Number of subjects: 0
Study: 24775991

Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin 3 mcg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin 1 mcg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (0 mcg/kg)
Number of subjects: 45
Study: 22726581

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy with concomitant cisplatin
Number of subjects: 213

Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy without concomitant cisplatin
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Advanced N-classification
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Technically unresectable disease
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Weight loss ratio
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Supportive measures
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Severe acute dysphagia
Number of subjects: 213
Study: 20385998

Group type: EXPERIMENTAL
Intervention: Pegylated interferon Alfa-2b (PEG-IFN)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 220
Study: 18284597

Group type: EXPERIMENTAL
Intervention: RB006 (0.75 mg kg(‐1) intravenous bolus) followed by RB007 (2:1 to 0.125:1 antidote/drug ratio, 1.5 mg kg(‐1) to 0.094 mg kg(‐1))
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RB007 (antidote)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 39
Study: 15868120

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 25620

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 25620

Group type: EXPERIMENTAL
Intervention: Combination of Telmisartan and Ramipril
Number of subjects: 25620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25620
Study: 11837528

Group type: EXPERIMENTAL
Intervention: Speech and language therapy for aphasia following stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic reviews in rehabilitation
Number of subjects: 0
Study: 9522243

Group type: EXPERIMENTAL
Intervention: Topical isotretinoin gel 0.05%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical retinoic acid cream 0.05%
Number of subjects: 30
Study: 7643294

Group type: EXPERIMENTAL
Intervention: Revised version of SPPA
Number of subjects: 11315

Group type: COMPARATOR
Intervention: Original SPPA
Number of subjects: 11315
Study: 2692983

Group type: EXPERIMENTAL
Intervention: Type A Behavior Pattern (TABP) assessment using the MYTH teacher rating scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Competition subscale of TABP
Number of subjects: 0
Study: 385402

Group type: EXPERIMENTAL
Intervention: 2 ml of betamethasone dipropionate + betamethasone phosphate (Diprospan)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 2 ml of methylprednisolone acetate (Depomedrol)
Number of subjects: 42
Study: 30852786

Group type: EXPERIMENTAL
Intervention: Question Prompt Sheet (QPS)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Question Listing (QL)
Number of subjects: 324
Study: 29099399

Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 1212
Study: 28594150

Group type: COMPARATOR
Intervention: Cortical thickness analysis using the Freesurfer DK atlas and DS atlas
Number of subjects: 222

Group type: COMPARATOR
Intervention: Surface-based morphometry (SBM)
Number of subjects: 222
Study: 26444128

Group type: EXPERIMENTAL
Intervention: Prophylactic balloon catheters
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no balloon catheters)
Number of subjects: 27
Study: 23494328

Group type: EXPERIMENTAL
Intervention: Immune No. 2 plus HAART
Number of subjects: 233
Study: 21875604

Group type: EXPERIMENTAL
Intervention: Mixed meal drink
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control drink (water)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 39
Study: 19453049

Group type: EXPERIMENTAL
Intervention: Sedation with midazolam 0.1 mg/kg, propofol 1 mg/kg, and fentanyl 1 microg/kg intravenously
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline as a placebo
Number of subjects: 90
Study: 16442399

Group type: EXPERIMENTAL
Intervention: 1.8 g of soy stanols
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 14586625

Group type: EXPERIMENTAL
Intervention: HBO therapy (Hyperbaric oxygen) added to steroids, plasma expander dextrans, diazepam, pentoxiphylline and salt restriction
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional treatment (steroids, plasma expander dextrans, diazepam, pentoxiphylline and salt restriction)
Number of subjects: 51
Study: 11195740

Group type: EXPERIMENTAL
Intervention: Chiron Technolas 217‐C excimer laser
Number of subjects: 28
Study: 9621828

Group type: EXPERIMENTAL
Intervention: Moderately fluent processing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Highly fluent processing
Number of subjects: 0
Study: 8158762

Group type: EXPERIMENTAL
Intervention: Microvascular artery bypass surgery
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Dorsal penile artery segments
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Inferior epigastric artery segments
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Deep dorsal vein segments
Number of subjects: 111
Study: 3679620

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (60 mg single dose) - Resilar
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (60 mg single dose) - Redol comp.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (60 mg single dose) - Extuson
Number of subjects: 10
Study: 29845764

Group type: EXPERIMENTAL
Intervention: LE-tablet computer use
Number of subjects: 9

Group type: COMPARATOR
Intervention: Printed materials
Number of subjects: 9
Study: 27435437

Group type: EXPERIMENTAL
Intervention: Hydromorphone/naloxone (4:1 ratio)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydromorphone/naloxone (2:1 ratio)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydromorphone/naloxone placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydromorphone/naloxone (6:1 ratio)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydromorphone/naloxone (8:1 ratio)
Number of subjects: 12
Study: 25194409

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 24199672

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural treatment (ICBT) supported by short face-to-face consultations (MoodGYM)
Number of subjects: 14
Study: 21387017

Group type: EXPERIMENTAL
Intervention: Second-order (contrast-based) visual motion stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-order (luminance-based) motion stimuli
Number of subjects: 0
Study: 18310180

Group type: EXPERIMENTAL
Intervention: Repetition of sexual communication with parents
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Breadth of sexual communication with parents
Number of subjects: 312
Study: 16969350

Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant chemotherapy (UFT 400 mg day-1 for 1 year) in stage I patients (group B)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Surgery alone in stage I patients (group A)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy (cisplatin and vindesine followed by UFT) in stage II or IIIA patients (group D)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Surgery alone in stage II or IIIA patients (group C)
Number of subjects: 267
Study: 14551895

Group type: EXPERIMENTAL
Intervention: DNA ME-TRAP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MVA ME-TRAP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MVA ME-TRAP with prior DNA ME-TRAP immunization
Number of subjects: 0
Study: 10992834

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rocuronium (0.6 mg kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rocuronium (0.9 mg kg‐1)
Number of subjects: 0
Study: 8804380

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis C vaccine
Number of subjects: 0
Study: 1607435

Group type: COMPARATOR
Intervention: Placebo dentifrice (0 ppm F)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 250-ppm-F dentifrice
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 1000-ppm-F dentifrice
Number of subjects: 19
Study: 3484960

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate with leucovorin calcium rescue (23 patients)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No chemotherapy (19 patients)
Number of subjects: 42
Study: 29615061

Group type: EXPERIMENTAL
Intervention: Multiple periods of outdoor free-play (3 separate periods, each at least 15 min, from 9 am to 3 pm)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Multiple periods of outdoor free-play
Number of subjects: 439

Group type: COMPARATOR
Intervention: Usual single continuous period of outdoor free-play
Number of subjects: 439
Study: 27479219

Group type: EXPERIMENTAL
Intervention: Slackline training (6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subjects with improved slackline performance
Number of subjects: 28
Study: 24982494

Group type: EXPERIMENTAL
Intervention: Referral Writer (RW) software program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard referral letters)
Number of subjects: 0
Study: 22796761

Group type: EXPERIMENTAL
Intervention: Single subcutaneous injection of CMAB001 at doses of 0.5, 1.0, or 2.0 mg/kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous injections of CMAB001 at a dose of 1.0 mg/kg for 7 weeks
Number of subjects: 34
Study: 20163324

Group type: EXPERIMENTAL
Intervention: Albuterol/ipratropium bromide combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipratropium bromide
Number of subjects: 0